Eagle Asset Management Inc. Acquires 3,553 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Eagle Asset Management Inc. lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 38.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,733 shares of the medical research company’s stock after buying an additional 3,553 shares during the period. Eagle Asset Management Inc.’s holdings in IQVIA were worth $2,791,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Activest Wealth Management bought a new position in shares of IQVIA in the third quarter worth $95,000. Thompson Siegel & Walmsley LLC increased its holdings in IQVIA by 21.9% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 22,292 shares of the medical research company’s stock valued at $5,283,000 after buying an additional 4,000 shares during the period. Intech Investment Management LLC acquired a new position in shares of IQVIA in the 3rd quarter valued at approximately $223,000. Citizens Financial Group Inc. RI boosted its position in shares of IQVIA by 19.8% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 2,463 shares of the medical research company’s stock worth $584,000 after acquiring an additional 407 shares in the last quarter. Finally, EULAV Asset Management raised its position in IQVIA by 4.4% during the third quarter. EULAV Asset Management now owns 309,000 shares of the medical research company’s stock valued at $73,224,000 after purchasing an additional 13,000 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on IQV. TD Cowen lowered their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. The Goldman Sachs Group decreased their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Evercore ISI cut their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Price Performance

IQV stock opened at $204.02 on Tuesday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The company’s fifty day simple moving average is $221.96 and its 200 day simple moving average is $226.98. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a market cap of $37.03 billion, a price-to-earnings ratio of 26.77, a PEG ratio of 2.08 and a beta of 1.51.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.